Department of Neurology, University of KwaZulu Natal, Berea, South Africa.
PLoS One. 2010 Dec 22;5(12):e15664. doi: 10.1371/journal.pone.0015664.
BACKGROUND/OBJECTIVE: The diagnosis of tuberculous meningitis (TBM) in resource poor TB endemic environments is challenging. The accuracy of current tools for the rapid diagnosis of TBM is suboptimal. We sought to develop a clinical-prediction rule for the diagnosis of TBM in a high HIV prevalence setting, and to compare performance outcomes to conventional diagnostic modalities and a novel lipoarabinomannan (LAM) antigen detection test (Clearview-TB®) using cerebrospinal fluid (CSF).
Patients with suspected TBM were classified as definite-TBM (CSF culture or PCR positive), probable-TBM and non-TBM.
Of the 150 patients, 84% were HIV-infected (median [IQR] CD4 count = 132 [54; 241] cells/µl). There were 39, 55 and 54 patients in the definite, probable and non-TBM groups, respectively. The LAM sensitivity and specificity (95%CI) was 31% (17;48) and 94% (85;99), respectively (cut-point ≥ 0.18). By contrast, smear-microscopy was 100% specific but detected none of the definite-TBM cases. LAM positivity was associated with HIV co-infection and low CD4 T cell count (CD4<200 vs. >200 cells/µl; p = 0.03). The sensitivity and specificity in those with a CD4<100 cells/µl was 50% (27;73) and 95% (74;99), respectively. A clinical-prediction rule ≥ 6 derived from multivariate analysis had a sensitivity and specificity (95%CI) of 47% (31;64) and 98% (90;100), respectively. When LAM was combined with the clinical-prediction-rule, the sensitivity increased significantly (p<0.001) to 63% (47;68) and specificity remained high at 93% (82;98).
Despite its modest sensitivity the LAM ELISA is an accurate rapid rule-in test for TBM that has incremental value over smear-microscopy. The rule-in value of LAM can be further increased by combination with a clinical-prediction rule, thus enhancing the rapid diagnosis of TBM in HIV-infected persons with advanced immunosuppression.
背景/目的:在资源匮乏的结核病流行环境中,结核性脑膜炎(TBM)的诊断具有挑战性。目前用于快速诊断 TBM 的工具准确性并不理想。我们试图在 HIV 高发环境中建立一种用于 TBM 诊断的临床预测规则,并将其与传统诊断方法和新型脂阿拉伯甘露聚糖(LAM)抗原检测试验(Clearview-TB®)进行比较,该试验使用脑脊液(CSF)进行检测。
将疑似 TBM 的患者分为明确-TBM(CSF 培养或 PCR 阳性)、可能-TBM 和非-TBM。
在 150 名患者中,84%为 HIV 感染者(中位数[IQR]CD4 计数=132[54;241]个/µl)。明确、可能和非 TBM 组的患者分别为 39、55 和 54 例。LAM 的敏感性和特异性(95%CI)分别为 31%(17;48)和 94%(85;99)(截点≥0.18)。相比之下,涂片镜检的特异性为 100%,但未检测到任何明确-TBM 病例。LAM 阳性与 HIV 合并感染和低 CD4 T 细胞计数(CD4<200 与>200 个/µl;p=0.03)相关。在 CD4<100 个/µl 的患者中,敏感性和特异性分别为 50%(27;73)和 95%(74;99)。多变量分析得出的临床预测规则≥6 具有 47%(31;64)的敏感性和 98%(90;100)的特异性。当 LAM 与临床预测规则结合时,敏感性显著增加(p<0.001)至 63%(47;68),特异性仍保持在 93%(82;98)的高水平。
尽管 LAM ELISA 的敏感性较低,但它是一种准确的 TBM 快速确诊试验,其价值高于涂片镜检。LAM 的规则纳入值可以通过与临床预测规则结合进一步提高,从而增强对 CD4 严重抑制的 HIV 感染者 TBM 的快速诊断。